THE GENE EXPRESSION SIGNATURE MODULATED BY DUPILUMAB IS HIGHLY CORRELATED WITH EOSINOPHILIC ESOPHAGITIS HISTOLOGICAL SEVERITY

Margaret H. Collins  ¹     Jennifer D. Hamilton  ²     Wei Keat Lim  ²     Sara Hamon  ²     Matthew F. Wipperman  ²     Allen Radin  ²     Mirna Chehade  ³     Ikuo Hirano  ⁴     Evan S. Dellon  ⁵     Sivan Harel  ⁵     William Brian  ⁶     Leda Mannent  ⁷     Marc E. Rothenberg  ^7    
1 Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, United States
² Regeneron Pharmaceuticals, Inc., Tarrytown, United States
³ Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, United States
⁴ Northwestern University Feinberg School of Medicine, Chicago, United States
⁵ University of North Carolina School of Medicine, Chapel Hill, United States
⁶ Sanofi, Bridgewater, United States
⁷ Sanofi, Chilly-Mazarin, France

Topic
Disease Mechanisms, Gut Microbiota, Histopathology, Immunology, Oesophagus, Small Intestine & Nutrition

Session
Eosinophilic esophagitis: A better understanding to improve treatment

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)